Exam 2: Lecture X, GI System Flashcards
Drugs for GI Disorders
Drugs for acid-peptic disease
Drugs to promote GI motility
Antidiarrheal agents
Drugs for acid-peptic disease
antacids Mucosal Protective agents PPI H2 antagonists antibiotics
Antacids are….
physical agents directly reacting with protons in the lumen of stomach
Typical Antacids
Sodium Bicarb - Alka Seltzer
Calcium carbo - Tums
Most popular antacids in USA….
are weak bases
Mg + Al Hydroxide
“Milk of Magnesia
Mg Hydroxide
strong laxative effect
Alu-Cap, Aludrox, Gaviscon
Al Hydroxide
constipating effect
Sucralfate (Al sucrose sulfate)
Poorly soluble molecule
**Creates protective coating over the ulcer
Accelerates the healing of peptic ulcers
Reduces the recurrence rate
Undergoes polymerization in the acid environment of the stomach
Polymer bind to the erosion in the stomach
**Due to poor solubility, drug has no significant systemic effect
**Mechanism of action is not clear
Sucralfate is a negatively charged small molecule
Positively charged proteins are at the base of ulcer or erosion
A physical barrier is formed
Restricts further acidic damage
Bismuth compounds:
Bismuth subsalicyte = bismuth + salicylate
Bismuth subcitrate potassium
Bismuth coats ulcers and erosions
Creates a protective layer against acids and pepsin
Stimulates mucus prostaglandins and bicarbonate secretion
Bismuth has direct antimicrobial effects
Bismuth is also used for treatment of dyspepsia and acute diarrhea
Misoprostol (methyl analog of PGE1)
Mucosal Protective Agent
Stimulates mucus and bicarbonate secretion
Enhances mucosal blood flow
Binds to prostaglandin receptors on parietal cells
Reduces histamine-stimulated cAMP production
Causes modest acid inhibition
Adverse effects: not to be used during pregnancy
PPI info
Agents introduced in 1980th
Efficacious agents
Major role – treatment of acid-peptic disorders
Proton pump inhibitors – mostly prescribed drugs
Characterized by an outstanding efficacy and safety
Rapid first-pass effect – mostly through hepatic metabolism
Short half-life
Up to 3-4 days required for acid-inhibiting potential
From pharmacokinetic perspective – ideal drugs
PPI drugs
Omeprazole (Prilosec, Zegerid) Esomeprazole (Nexium) Lansoprazole (Prevacid) Dexlansoprazole (Dexilant) Rabeprazole (Aciphex) Pantoprazole (Protonix)
all somewhat similar structure, but different MOA. Admin as inactive prodrugs
Omeprazole (Zegerind, Prilosec OTC)
prototype PPI
Useful to treat Gastric reflux, Zolligner-Ellison syndrome with a gastrin-secretin tumor
irreversibly binds proton pump, located in luminal membrane of parietal cell.
inhibition lasts for 48 hrs
H2 blockers
Cimetidine (Tagamet)
Ranitidine (Zantac)
Famotidine (Pepsid)
Nizatidine (Axid)
advent of PPI decreased use of H2 blockers
Cimetidine (Tagamet)
Relatively selective and have no effect upon H1 receptors
Relatively non-toxic - can be given in large doses
Main application in acid-peptic disease - especially duodenal ulcer
Accelerates healing and prevents recurrences
Recurrences may be prevented by a single bedtime dose
Also effective in healing and preventing severe gastric peptic ulcers
Very helpful in controlling acid hypersecretion
Very helpful in treatment of GI bleeding and diarrhea
May be used to treat gastroesophageal efflux disease (GERD)